CONTINUATION TRIAL OF LYMPHOSTAT-B ANTIBODY

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 这是一项在SLE受试者中进行的多中心、开放标签、持续试验，这些受试者在LBSL 02的II期研究中获得了令人满意的缓解。 受试者将每28天静脉内接受10 mg/kg LymphStat-B，持续1至2小时。 首次输注将在2小时内进行。 如果未发生输注反应，则将在1.5小时内输注第2剂。 如果未发生输注反应，则第3次和后续剂量将在1小时内输注。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a multi-center, open-label, continuation trial of LymphoStat-B in SLE subjects who achieved a satisfactory response in the Phase 2 study of LBSL02. Subjects will receive 10 mg/kg of LymphStat-B every 28 days intravenously over a period of 1 to 2 hours. The first infusion will be given over 2 hours. If no infusion reactions occur, then the 2nd dose will be infused over 1.5 hours. If no infusion reactions occur, then the 3rd and subsequent doses will be infused over 1 hour.